drugset / Trial / NCT05263492
Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer
NaSingle-groupOpen-labelTreatment
Summary
Determine the efficacy of the combination of lenvatinib and pembrolizumab in Black participants
Timeline
- Start
- 2022-04-01
- Primary completion
- 2024-09-13
- Completion
- 2024-10-19
Outcome
Outcome not reported
Stopped (Enrollment): “Closed early due to low enrollment rates”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 20 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |